Literature DB >> 16822587

Effects of glucose-dependent insulinotropic peptide on behavior.

Ke-Hong Ding1, Qing Zhong, Ding Xie, Huan-Xin Chen, Mary Anne Della-Fera, Roni J Bollag, Wendy B Bollag, Ravinder Gujral, Baolin Kang, Supriya Sridhar, Clifton Baile, Walton Curl, Carlos M Isales.   

Abstract

Glucose-dependent insulinotropic peptide (GIP) is an incretin hormone that rises rapidly in response to nutrient ingestion. The GIP receptor is widely expressed in the brain including the brain stem, telencephalon, diencephalon, olfactory bulb, pituitary, and cerebellum. Until recently it was not clear what the endogenous ligand for this receptor was because no GIP expression had been demonstrated in the brain. GIP synthesis has now been documented in the dentate gyrus of the hippocampus. To define GIP effects on behavior we utilized a mouse model a GIP-overexpressing transgenic mouse (GIP Tg). Specifically, anxiety-related behavior, exploration, memory, and nociception were examined. Compared to age-matched adult male C57BI/6 controls GIP Tg mice displayed enhanced exploratory behavior in the open-field locomotor activity test. GIP Tg mice also demonstrated increased performance in some of the motor function tests. These data suggest that the GIP receptor plays a role in the regulation of locomotor activity and exploration. To our knowledge, this is the first report of effects of GIP on behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822587     DOI: 10.1016/j.peptides.2006.05.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  17 in total

Review 1.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

Review 2.  Bidirectional metabolic regulation of neurocognitive function.

Authors:  Alexis M Stranahan; Mark P Mattson
Journal:  Neurobiol Learn Mem       Date:  2011-01-12       Impact factor: 2.877

3.  Central GIP signaling stimulates peripheral GIP release and promotes insulin and pancreatic polypeptide secretion in nonhuman primates.

Authors:  Paul B Higgins; Robert E Shade; Irám P Rodríguez-Sánchez; Magdalena Garcia-Forey; M Elizabeth Tejero; V Saroja Voruganti; Shelley A Cole; Anthony G Comuzzie; Franco Folli
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-08-16       Impact factor: 4.310

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.

Authors:  Alexandre Dal-Pan; Stéphane Blanc; Fabienne Aujard
Journal:  BMC Physiol       Date:  2010-06-22

6.  (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

Authors:  P L McClean; N Irwin; K Hunter; V A Gault; P R Flatt
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

7.  Impact of glucose-dependent insulinotropic peptide on age-induced bone loss.

Authors:  Ke-Hong Ding; Xing-Ming Shi; Qing Zhong; Baolin Kang; Ding Xie; Wendy B Bollag; Roni J Bollag; William Hill; Walter Washington; Qing-Sheng Mi; Karl Insogna; Norman Chutkan; Mark Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2008-04       Impact factor: 6.741

8.  Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice.

Authors:  F Isken; M O Weickert; M H Tschöp; R Nogueiras; M Möhlig; A Abdelrahman; S Klaus; B Thorens; A F Pfeiffer
Journal:  Diabetologia       Date:  2009-07-31       Impact factor: 10.122

9.  Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice.

Authors:  Frank Isken; Andreas F H Pfeiffer; Rubén Nogueiras; Martin A Osterhoff; Michael Ristow; Bernard Thorens; Matthias H Tschöp; Martin O Weickert
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-27       Impact factor: 4.310

10.  Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

Authors:  V A Gault; P L McClean; R S Cassidy; N Irwin; P R Flatt
Journal:  Diabetologia       Date:  2007-06-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.